You are looking at a spirometry report and the patient’s FEV1 dropped by 20% after inhaling methacholine. Is that enough to call it asthma? Not always. Bronchoprovocation testing is one of the most sensitive tools we have for diagnosing airway hyperresponsiveness. But interpreting the results requires more than just checking a number. You have to consider the dose, the patient’s baseline, and the clinical picture. Let’s walk through how to interpret bronchoprovocation testing step by step, with the practical details that matter in your clinic or pulmonary function lab.

Understanding the basics of bronchoprovocation testing

Bronchoprovocation testing measures airway responsiveness to inhaled agents like methacholine, histamine, or mannitol. The methacholine challenge test is the most widely used in the United States. During the test, the patient inhales incremental doses of methacholine, and after each dose you measure FEV1. The endpoint is the concentration or dose that causes a 20% drop from the baseline FEV1. That value is called PC20 (provocative concentration) or PD20 (provocative dose).

The test is indicated when asthma is suspected but spirometry is normal or near normal. It can also help assess severity or response to treatment. In 2026, newer protocols are shortening test times without losing accuracy, but the core interpretation method remains the same.

The key metrics you need to track

When you read the report, focus on three numbers.

• PC20 – the concentration of methacholine (in mg/mL) that triggers a 20% fall in FEV1.
• PD20 – the cumulative dose (in micromoles) that triggers the same fall.
• The dose response slope – some labs also report the linear slope of FEV1 decline across doses. A steep slope suggests higher reactivity even if PC20 is borderline.

Most labs use a cutoff of PC20 ≤ 8 mg/mL to define a positive test. But cutoffs vary by institution. The American Thoracic Society guidelines recommend interpreting PC20 as follows:

• PC20 < 1 mg/mL: strongly positive (high airway hyperresponsiveness)
• PC20 1 – 4 mg/mL: moderate positive
• PC20 4 – 8 mg/mL: borderline positive (needs clinical correlation)
• PC20 > 8 mg/mL: negative, but mild responsiveness may still be present

Do not rely on a single cutoff. A patient with a PC20 of 6 mg/mL and classic asthma symptoms may still have asthma. A patient with PC20 of 2 mg/mL and no symptoms may have silent airway hyperresponsiveness (e.g., in allergic rhinitis).

A three step process for interpreting results

Here is a practical approach you can use every time you review a bronchoprovocation report.

1. Check the baseline spirometry and reversibility. Ensure the pre challenge FEV1 is at least 70% of predicted or above 1.5 L in adults. A low baseline can increase risk of excessive bronchoconstriction. If the patient already has airflow obstruction, the test may be contraindicated. Also note if any bronchodilator was withheld (short acting beta agonists: 8 hours, long acting: 24 hours or more).

2. Locate the PC20 and note the total dose. Look at the chart. Did the patient reach a 20% fall? At what concentration? Was the test stopped because of symptoms or because the maximum dose was reached? A negative test (no 20% drop at the highest dose) makes asthma very unlikely, with a negative predictive value above 95%.

3. Interpret the shape of the dose response curve. A plateau in FEV1 decline after a fall suggests a positive test with mild hyperresponsiveness. A continuous decline without a plateau indicates more severe reactivity. Also watch for a late response; if FEV1 continues to fall after the last dose, that can indicate more persistent airway inflammation.

Common pitfalls in interpretation

Even experienced clinicians can get tripped up. Here is a table of frequent mistakes and how to avoid them.

Pitfall	Why it happens	Correct approach
Calling a PC20 of 8 mg/mL positive without clinical correlation	Cutoff is statistical, not absolute. Many healthy people have PC20 between 4 and 8.	Always ask: do symptoms match? Use bronchodilator response or peak flow variability to confirm.
Interpreting a negative test as ruling out all forms of asthma	Some patients with cough variant asthma or exercise induced asthma can have normal methacholine challenge.	Consider a eucapnic voluntary hyperpnea test or mannitol challenge when suspicion remains.
Ignoring medication withdrawal errors	Patient took albuterol 4 hours before the test. That can suppress reactivity.	Repeat the test after proper washout. Document medications in the report.
Overreading a drop caused by coughing or poor effort	A 20% drop that is not reproducible or occurs at low dose with erratic effort may be artifact.	Repeat the dose. Check if the FEV1 improvement after bronchodilator confirms true bronchoconstriction.
Using a single PC20 cutoff for children	Children have smaller airways and may have lower PC20 thresholds even without asthma.	Use age adjusted reference values. PC20 < 2 mg/mL is more specific in children.

When a positive test does not mean asthma

Airway hyperresponsiveness is not synonymous with asthma. Several conditions can produce a positive bronchoprovocation test.

• Allergic rhinitis (up to 50% of patients have positive methacholine challenge)
• COPD, especially in smokers with chronic bronchitis
• Cystic fibrosis
• Bronchiectasis
• Congestive heart failure (cardiac asthma)
• Exposure to irritants (e.g., occupational chemicals, smoke)
• Recent respiratory infection (viral bronchitis can cause transient hyperresponsiveness)

A positive test supports asthma but does not establish it by itself. You need to see symptoms like wheezing, chest tightness, or cough that are variable and reversible. Combine the test with monitoring of peak expiratory flow variability over two weeks. If the patient has both a positive challenge and evidence of diurnal variation >20%, the diagnosis is much more secure.

Factors that can affect test results

• Timing of day: airway responsiveness can be higher in the early morning.
• Menstrual cycle: some women show increased reactivity premenstrually.
• Exercise: avoid strenuous activity for 4 hours before testing.
• Caffeine: can blunt bronchoconstriction. Advise no caffeine for 6 hours.
• Smoking: active smokers may have elevated PC20 due to chronic irritation, but also can have reduced responsiveness from desensitization.
• Medications: beta blockers, even topical eyedrops, can increase airway reactivity.

Make sure your lab checklist includes these variables. Document them so you can interpret the result correctly.

Clinical pearls from the lab

“I always tell my fellows: the methacholine challenge is like a fire drill. You are testing if the fire alarm goes off at a low dose of smoke. But some buildings have sensitive alarms even when there is no fire. Always look for the smoke of symptoms.”
— Dr. Patricia Nguyen, pulmonologist at a major academic center (personal communication, 2026)

That advice captures the spirit of bronchoprovocation interpretation. The test is a tool, not a verdict.

Remember that the PC20 is a continuous measure. A patient who drops 19% at the highest dose does not suddenly become normal. You can consider that “borderline positive” and follow clinically. In practice, many labs now use a 15% fall as an alternative endpoint for some protocols, especially in research. But the ATS still recommends 20% as the standard.

Integrating results with other clinical data

When you interpret a bronchoprovocation test, place it in the full diagnostic picture. Combine it with:

• Spirometry with bronchodilator response (FEV1 increase >12% and 200 mL)
• Serial peak flow measurements
• Exhaled nitric oxide (FeNO) – if elevated, suggests eosinophilic airway inflammation
• Allergy testing (skin prick or specific IgE) – helps identify triggers

For example, a patient with positive methacholine challenge (PC20 4 mg/mL), FeNO of 50 ppb, and symptoms after cat exposure has a high likelihood of asthma. Another patient with the same PC20 but no symptoms, normal FeNO, and no allergies may simply have asymptomatic hyperresponsiveness. You can reassure them and avoid overtreatment.

In 2026, some centers are integrating machine learning models that combine spirometry, challenge data, and biomarkers to generate a probability score for asthma. These models are still in validation, but they promise to reduce overdiagnosis. You can read more about this in our article on harnessing artificial intelligence to improve respiratory disease diagnosis in 2026.

Advances in 2026 and the future of bronchoprovocation

Newer bronchoprovocation agents like mannitol (offered as a dry powder) are gaining popularity because they do not require nebulization and have fewer side effects. Mannitol challenge interpretation uses a different cutoff (PD15 > 635 mg is negative). The test is more specific for asthma but less sensitive than methacholine.

Also, impulse oscillometry (IOS) is being used as an alternative to FEV1 in some centers, especially for patients who cannot perform forced maneuvers. IOS measures airway resistance and reactance. A positive IOS response during challenge may be more sensitive for small airway involvement.

For a broader view of how diagnostic tools are evolving, see our update on innovative diagnostic tools transforming respiratory disease management.

Putting it all together in your practice

Bronchoprovocation testing interpretation is straightforward once you remember the basics: know the PC20 cutoff, check the clinical context, rule out confounders, and never diagnose asthma from the test alone. Use the test to confirm or exclude, not to replace your clinical judgment.

Next time you get a report, walk through the three step process. If the numbers do not match the story, dig deeper. You might save a patient from years of unnecessary inhalers. And if the story fits, you can treat with confidence.

Thank you for taking the time to refine your interpretation skills. Keep asking questions and stay curious.